Catalyst Pharmaceutical Partners Announces Presentation to be Made at the American Epilepsy Society's 65th Annual Meeting
The poster, entitled "CPP-115, a new GABA transaminase inhibitor, suppresses infantile spasms in the rat multiple-hit model," was authored by
About The Study
IS is an infantile epileptic encephalopathy associated with cognitive and behavioral deficits and increased mortality. Vigabatrin (CPP-109), a GABA transaminase inhibitor, is one of the few treatments available for IS. The study tested the efficacy in suppressing spasms and tolerability profile of Catalyst's new vigabatrin analog, CPP-115, in the multiple-hit rat model of ACTH-refractory symptomatic IS (DLP model). This model recreates the spasms, ictal EEG correlates, interictal EEG abnormalities, and neurodevelopmental decline observed in symptomatic infantile spasms observed in babies. In the later stages of development, the rats also develop learning, memory, and autistic like deficits similar to those observed in humans. It is therefore, currently one of the best models available for the evaluation of pharmacotherapies for the treatment of ACTH resistant infantile spasms. In previous studies, vigabatrin only transiently suppressed spasms in the DLP model (postnatal day 5 (PN5) only), but was associated with increased sedation and consequently mortality due to poor feeding. The poster describes the following study conclusions:
1. CPP-115 suppresses spasms in the multiple-hit model of IS, with onset of effect as early as the day after the first dose.
2. The therapeutic doses of CPP-115 were well tolerated in developing rat pups.
3. CPP-115 showed efficacy at lower doses which were better tolerated than the previously tested therapeutic vigabatrin (CPP-109) doses.
The poster can be viewed on
This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties which may cause the Company's actual results in future periods to differ materially from forecasted results. A number of forward looking statements contained in this press release, including whether CPP-115 will be an effective treatment for IS in humans, whether CPP-115 will ever be approved for commercialization, and other forward looking statements contained in the Company's filings with the
Patrick J. McEnanyChief Executive Officer Catalyst Pharmaceutical Partners(305) 529-2522 firstname.lastname@example.org Melody CareyCo-President Rx Communications Group(917) 322-2571 email@example.com
News Provided by Acquire Media